Viking Therapeutics stock declined 2.1% despite recent positive developments. The company reported positive Phase 1 trial results for its oral weight-loss drug VK2735, which showed obese patients experienced significant dose-dependent decreases in body weight. This follows earlier success with an injectable version of the same drug. Zacks Research upgraded the stock from strong sell to hold on February 20, 2026, while the sell-side consensus remains a Moderate Buy with an average price target of $87.80. However, the company reported a quarterly EPS loss of negative $1.38, missing estimates by $0.49. Significant insider selling occurred in early January, with the CFO and COO each selling approximately $1.9 million in shares. The stock trades near $31 with a $3.59 billion market cap.
Read full analysisViking Therapeutics stock declined 2.1% despite recent positive developments. The company reported positive Phase 1 trial results for its oral weight-loss drug VK2735, which showed obese patients experienced significant dose-dependent decreases in body weight. This follows earlier success with an injectable version of the same drug. Zacks Research upgraded the stock from strong sell to hold on February 20, 2026, while the sell-side consensus remains a Moderate Buy with an average price target of $87.80. However, the company reported a quarterly EPS loss of negative $1.38, missing estimates by $0.49. Significant insider selling occurred in early January, with the CFO and COO each selling approximately $1.9 million in shares. The stock trades near $31 with a $3.59 billion market cap.
Viking Therapeutics is a clinical-stage biotech developing treatments for obesity and metabolic diseases, with its lead candidate VK2735 — a GLP-1 receptor agonist — in both injectable and oral formulations competing in the same space as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. The company has roughly $706 million in cash but no approved products or revenue, making it a high-volatility name driven entirely by clinical milestones. Today's modest pullback follows a sharp rally on positive Phase 1 data for the oral VK2735 pill, which showed significant dose-dependent weight loss and is expected to advance into Phase 2 trials later this year.